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Abstract 
Introduction: Colorectal cancer (CRC) is a common malignancy and ranking fourth 
among the causes of cancer-related deaths globally. Its incidence has increased in recent 
decades, and now more than one million CRC patients are diagnosed and thousands die 
annually. The 5-year survival rate varies with the stage at diagnosis, being approximately 
90% in the early stages of disease, and less than 10% in advanced disease. Non-
alcoholic fatty liver disease (NAFLD), which is a major cause of chronic liver disease, and 
characterized by the accumulation of fat in hepatocytes, has also emerged as a risk factor 
for CRC, and to be related with the development of colorectal polyps.  
Areas covered: The purpose of this current review is to summarize the main findings of 
studies that have investigated the role of NAFLD in development of CRC. 
Expert commentary: Various molecular pathways, are altered during the development 
of NAFLD, which are also important in CRC tumorigenesis. There is growing body of 
evidence showing the potential role of activation of pro-inflammatory, disruption of anti-
inflammatory pathways, increasing the activity of pathways involved in cell 
proliferation/survival. Thus targeting these deregulated pathways via novel inhibitors can 
be a potential therapy for CRC prevention in cases with NAFLD.  
 
Keywords: non-alcoholic fatty liver disease, colorectal cancer, polyp, metabolic 
syndrome, diabetes, dyslipidemia 
  
1. Introduction 
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and 
ranks fourth among the causes of cancer-related deaths globally [1]. Recently, there has 
been a reported increase in the incidence of CRC [2]. It is expected that about 2.2 million 
new CRC cases are diagnosed annually with more than 1 million cancer deaths projected 
for 2030 [3]. The 5-year survival rate varies with the stage at which it diagnosed, being 
approximately 90% in early stage of disease, and less than 10% in advanced stage [4]. 
CRC carcinogenesis is a multistep process and usually takes 10-15 years to develop, 
initially as a noncancerous polyp [1]. Due to high costs associated with screening for 
CRC, individuals who do not show symptoms and are not at risk, do not usually undergo 
assessment. As a result, identifying a high-risk population has been an emergent issue 
[5]. Recently, one of the major causes of chronic liver disease, non-alcoholic fatty liver 
disease (NAFLD), has also emerged as a risk factor for CRC, and to be related to the 
development of colorectal polyp and also to the pathogenesis of CRC. 
Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of 
fat in the liver. The global prevalence of NAFLD is increasing worldwide [6]. NAFLD refers 
to a range of changes from initial steatohepatitis, and later to fibrosis and cirrhosis [7]. 
Among the causes of NAFLD are over-nutrition and its complications, such as weight 
gain, central obesity, insulin resistance, glucose intolerance, dyslipidemia and arterial 
hypertension and metabolic syndrome (MetS), which are amplified in individuals with 
genetic predispositions [8]. The relationship between NAFLD and conventional metabolic 
conditions including diabetes mellitus, obesity and dyslipidemia had been established 
previously [9]. Finding of recent studies revealed that NAFLD as a new potential risk factor 
for extra-hepatic cancers [10]. The purpose of this current review was to summarize the 
main findings of studies investigated the role of NAFLD in development of CRC. 
 
2. Non-alcoholic fatty liver disease overview 
2.1 Epidemiology and clinical features 
 The term NAFLD covers a range of liver conditions from simple steatosis to non-
alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma (HCC). 
NAFLD [11, 12, 13]. NAFLD which is the most common chronic liver conditions worldwide, 
is identified by accumulation of fat in the liver in the absence of chronic alcohol 
consumption or drinking alcohol less than 40g/day in the patient history [14]. The global 
prevalence of NAFLD in the adult population is evaluated to be about 24% [15, 16]. 
Furthermore, 3-10% of children is reported to have NAFLD [6]. The majority of NAFLD 
patients are asymptomatic. However, most of symptomatic patients have non-specific 
symptoms including feeling abdominal pain in right upper quadrant, fatigue and malaise 
[17]. 
 
2.2 Risk factors and pathogenesis 
There are several risk factors for NAFLD that include: male gender, obesity, insulin 
resistance (IR), type 2 diabetes mellitus, dyslipidemia and MetS [17]. The pathogenesis 
of NAFLD involves several stages. In the first stage, steatosis, is likely triggered by insulin 
resistance. The second stage entails oxidative stress and cytokines alteration which 
worsen the condition. The relationship between NAFLD and reduced insulin sensitivity 
due to impaired insulin signaling has been discussed by several researchers. Free fatty 
acid (FFA) form fat in diet can be esterified with glycerol in to triglycerides (TG) and 
subsequently stored in adipocytes. Insulin resistant related metabolic abnormalities occur 
when accumulation of fat in liver lowers insulin stimulated glucose uptake [18]. Elevated 
concentrations of FFAs and consequential lipotoxicity, insulin resistance, peripheral 
adipose tissue dysfunction and gastrointestinal derived endotoxins jointly play a role in 
activating and maintaining the production and release of pro-inflammatory cytokines, both 
on a systemic level and in the liver. Two main inflammatory pathways, c-Jun N-terminal 
kinase (JNK)/activator protein-1 (AP-1) pathway and IκB kinase (IKK)/nuclear factor-
kappa B (NF-κB) pathway, have crucial roles in the development of the chronic 
inflammatory state in NAFLD [19]. Connections have been made between hepatic FFAs 
flux, oxidative stress, response to endotoxins and cytokine production and activity, and 
individuals’ genetic makeup, particularly as indicated by single nucleotide polymorphisms, 
for NAFLD development and progression [19].  
 
2.3 Diagnosis and treatment 
The gold-standard method for diagnosis of NAFLD is by liver biopsy. Nevertheless, 
besides histology analysis, an excessive fat accumulation in the liver can be established 
using noninvasive diagnostic tests including ultrasonography, magnetic resonance 
imaging (MRI), computed tomography (CT) and transient elastography (fibroscan) [20]. 
Although Laboratory testing is insufficient of NAFLD diagnosis and also may be normal, 
however, especially elevated serum aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) are the most frequent abnormal biochemical tests. In most cases 
the AST-to-ALT ratio is less than 1 [17]. In addition, other biochemical tests consisting 
triglyceride level, gamma-glutamyltransferase and alkaline phosphatase may be 
increased [12]. The most widely accepted efficient therapeutic approach for NAFLD are 
dietary and lifestyle modification, increased physical activity and at least a 3% weight 
reduction [21].  
Medical therapies for targeting comorbidities of NAFLD, such as the use of insulin 
sensitizers such as metformin and thiazolidinedione in diabetic patients, lipid lowering 
agents like statin in dyslipidemia, antioxidants such as vitamin E and hepatoprotective 
agents like ursodeoxycholic acid (UDCA) may be useful in NAFLD treatment.  
Despite the lack of randomized clinical trials, a recent expert panel has discussed the 
pharmacological treatment for NASH using pioglitazone, statins and ezetimibe in-
combination or alone [22]. Among the other drugs reviewed were fibrates, simtuzumab 
and omega 3 fatty acids, that were considered to be drugs with equivocal effect on 
treatment of NAFLD [23]. An old and well known drug in this category is metformin. 
Metformin has the capacity to improve insulin resistance, and it has also been reported 
to be effective in treating NAFLD. Moreover, metformin can reduce the risk of developing 
hepatocellular carcinoma in those who have cirrhosis [24]. While there is an insufficient 
body of evidence available regarding the effect of metformin on the histopathological 
improvement in NAFLD liver, it seems that using this drug may improve the all-cause 
mortality of patients with NASH [25].  Besides improving liver function, it has been 
demonstrated that metformin can also decrease risk of colorectal malignancies in a dose 
dependent manner in diabetic patients [26, 27]. Emricasan a pan-caspase inhibitor has 
also been also used to treat NAFLD and liver fibrosis. However, the effect of such 
treatment on the development of colorectal tumors is not clearly established [28]. 
Although more research is needed it seems that other drugs including agonist of the 
farnesoid X receptor may have a role in improving liver inflammation and insulin sensitivity 
of diabetic patients and NAFLD as well as anti-proliferative effects on CRC cells by 
inducing cell cycle arrest [29, 30]. While the possible link between NAFLD and CRC 
development is emerging, it is appears important that future trials evaluate the effect of 
such drugs on CRC development in NAFLD patients. 
2.4 NAFLD and malignancies 
NAFLD is one of the most common chronic liver disease and its relationship with insulin 
resistance, diabetes and some cancers will increase its importance. It has been shown 
that malignancies are one of the most common causes of death among NAFLD patients. 
The association between NAFLD and developing some cancers is not clearly understood. 
A recent study by Kim et al. demonstrated the association between NAFLD and the 
incidence of malignancies [31], showing that NAFLD patients have higher rates of all 
cancers including hepatocellular carcinoma. Moreover, male NAFLD patients are more 
likely to develop CRC while the female are more likely to develop breast cancer. 
Regardless of cancer type, it seems likely that obesity plays a major role in the 
development of these various cancers in NAFLD. Metabolic and hormonal dysregulation 
together with the NAFLD itself in obese patients has been related to development of 
various cancers including breast cancer [31]. As we will discuss later, the systemic 
inflammatory disturbance during the development of NAFLD development and 
progression may be the cornerstone of the most of dysregulation in body system and 
development of cancers, especially colorectal cancer that is the focus of the present 
review. In brief, inflammation occurring during the development of NAFLD can affect liver 
and other organs including the gut, blood vessels and adipose tissue. The effect of 
inflammation on altered gut microbiota has also been linked to the development of several 
gastrointestinal malignancies. Moreover, increased leptin and reduced adiponectin is 
found in individuals with NAFLD and this has been linked to the development of colorectal 
malignancies. Insulin resistance caused by release of adipokines and free fatty acids as 
well as abnormal deposition of fat in different tissues will enhance NAFLD progression 
and development of colorectal tumors [32]. Regardless of the cause or effect relation 
between NAFLD and CRC, it has been reported that CRC patients with pre-existing 
NAFLD have a worse prognosis [33]. All of these findings indicate the importance of 
reviewing the role of NAFLD in CRC and highlighting the possible way ahead for further 
studies in this area.  
 
3. Colorectal cancer overview 
3.1 Epidemiology and clinical features 
CRC is the most prevalent gastrointestinal malignancy and ranks second among 
all cancer-related deaths in developed countries. Recently, there has been a significant 
elevation in the incidence of CRC [2]. Although both gender have been affected similarly 
but geographical differences have been observed in CRC incidence rate. Epidemiological 
studies have been indicated that more than 60% of new cases and CRC related deaths 
occur in high-income countries [3]. The highest incidence rates are reported from 
Australia and New Zealand, and European and North American countries. African and 
South-Central Asian countries show the lowest rates. Based on the degree of invasion, 
CRC is classified as early or advanced stage. In early stage CRC is ordinarily 
asymptomatic or exhibit with non-specific manifestations including change in bowel habit, 
loss of appetite, weight loss, anemia and abdominal pain. In more advance stages, tumor 
spreads by local invasion or distant metastasis and symptoms become more prominent. 
 
3.2 Risk factors and pathogenesis 
Geographical differences in the incidence of CRC seems to be due to differences 
in dietary and environmental factors, interacting with genetics factors [2].  Beside age and 
the genetic factors, the presence of inflammatory bowel disease, familial adenomatous 
polyposis (FAP), Lynch syndrome and environmental factors including nutritional 
practices, physical activity, obesity, smoking, alcohol consumption and over-consumption 
of red meat constitute the major risk factors for CRC [22]. Links between MetS, CRC and 
colorectal neoplasia (CRN) which share common risk factors have been examined in 
development of CRN. Several studies have revealed that metabolic syndrome 
significantly increases the risk of CRC or CRN (26, 27). In transition from normal 
colorectal epithelium to cancerous forms in CRC carcinogenesis, a number of various 
factors and signaling pathways are involved [16, 23, 24, 25, 26]. It is estimated that during 
lifetime between one third to one half of all individuals develop at least one adenoma [27]. 
Adenocarcinomas with glandular tissue origins constitute roughly 96% CRC cases. 
Although less than 10% of adenomas progress to cancer, adenomas, also referred to as 
adenomatous polyps, carry a comparatively larger risk of becoming cancerous. Insulin 
has been suggested as an agent of carcinogenesis of CRC. Further, elevated levels of 
plasma insulin and glucose, glucose intolerance, obesity and physical inactivity have 
been shown to be correlated with CRC [28]. Most cases of CRC develop via the adenoma-
carcinoma sequence. Adenomatous colorectal polyps are considered to be precursors of 
CRC. It has been reported that NAFLD, regardless of traditional CRC risk factors, is an 
important and independent risk factor for developing CRC [29]. Metabolic disturbances 
during NAFLD may act as a predisposing factor for developing cancer. This is expressed 
by alterations in several molecular and biological pathways. During development of 
NAFLD, some important molecular pathways in developing different cancers will be down 
or unregulated. Insulin resistance and metabolic syndrome has well-known changes in 
some molecular pathways, and are two common etiologies of NAFLD which are also 
considered to be important in developing different cancers such as CRC. The main trigger 
of developing neoplasms which are affected by these two conditions are initiated by a 
disruption in cellular microenvironment. Increased Insulin-like growth factor-1 (IGF-1) and 
insulin during insulin resistance will act as a precursor of developing CRC neoplasms 
mainly due to induction of cellular proliferation and inhibition of apoptosis [30]. Beside the 
role of insulin resistance in  NAFLD, there is a low inflammatory state which is usually 
aggravated by proinflammatory cytokines produced by liver and other cytokines such as 
IL-6 and TNF-a [31]. Moreover, the effect of different adipokines are prominent in 
developing alteration in tissue metabolism and cellular environment. Adiponectines will 
modulate the inflammation process and induce tumorogenesis [32]. All of these factors 
lead to a suitable environment for angiogenesis and proliferative state with decreased 
apoptosis (Figure 1).  
 
3.3 Diagnosis, staging, treatment and prognosis 
Colonoscopy with biopsy of any suspicious areas is generally regarded as the first 
choice for CRC diagnosis [5]. Screening colonoscopy is widely believed to be the most 
effective method to reduce the incidence of CRC and CRC mortality by removing 
precancerous polyps [33, 34]. In addition to physical examination, biochemical tests, and 
imaging such as computed tomography (CT) scan, magnetic resonance imaging (MRI), 
positron emission tomography (PET) scan could be beneficial in detection of CRC and its 
local or distant invasion. The stages of CRC are categorized as: (i) Stage I (CRC cells 
are limited in epithelial layer without invasion to deep layers of colorectal wall), (ii) Stage 
II (invasion of CRC cells into deep layers of colorectal wall), (iii) Stage III (invasion of CRC 
cells into regional lymph node) and (iv) Stage IV (distant metastasis). Treatment of CRC 
relies on disease stage and involves three main approaches: (i) surgery, (ii) 
chemotherapy and (iii) radiotherapy [1]. The most common protocol applied in 
chemotherapy is the FOLFOX protocol (including 5-Fluorouracil, Folinic Acid (Leucovorin) 
and Oxaliplatin) and CapeOx protocol (including capecitabine and oxaliplatin) [35]. In 
addition to conventional therapeutic approach, targeted therapeutic approaches may be 
used based on clinicopathological and molecular features of CRC tumors [1, 23, 24, 25]. 
CRC stage at treatment is largely associated with survival. The 5-year survival rate for 
patients with CRC can be as high as 90% for cancers detected at the early stages or as 
low as 10% when cancer cells have formed distant metastasis [36]. 
 
4. Role of non-alcoholic fatty liver disease in development of colorectal polyps 
Although several studies have attempted to identify a connection between 
colorectal adenomatous polyps and NAFLD, the results have not been in agreement. Still, 
most pointed to a positive correlation between NAFLD and colorectal adenomatous 
polyps [37]. Hwang et al. [38] were the first to try to investigate the link between NAFLD 
and colorectal adenomatous polyps. Analyzing 2917 patients who had undergone 
colonoscopy and assessing anthropometric measurements, biochemical tests for liver 
and metabolic function, and abdominal US, they showed that NAFLD was associated with 
colorectal adenomatous polyps. Further studies should be performed to confirm 
investigate NAFLD as a predictor for the development of colorectal adenomatous polyps 
and cancer [38]. In a retrospective cohort study of 5517 Korean women aged 35–80 years 
which diagnosed fatty liver diseases using abdominal US, Lee et al. [39] showed that 
NAFLD was significantly associated with an increased incidence of adenomatous polyps. 
Wong et al. [40] found that NAFLD is associated with increased prevalence of colorectal 
adenomatous polyps. Among the 29 patients in their study with advanced neoplasms, 13 
had isolated lesions in the right-sided colon. Further, for the most part, increased risk of 
adenomatous polyps was found in NASH subjects as opposed to those with simple 
steatosis. Wong et al. used proton magnetic resonance spectroscopy to diagnose 
NAFLD, in concert with liver biopsies for some patients. Stadlmayr et al. [41] explored the 
link between CRC and NAFLD in patients who had undergone colonoscopy, both male 
and female patients with NAFLD showed higher rate of adenomas. Also, tubular 
adenomas and adenomas of the rectum were observed to be more prevalent in men with 
NAFLD. For women with NAFLD however, more tubular adenomas with adenomas of the 
proximal colon were identified. In a retrospective assessment of patients who completed 
liver transplant evaluation Bhatt et al. [42] showed the higher prevalence of adenomatous 
polyps in NAFLD patient compared to patients with other forms of end stage liver disease. 
Furthermore, compared to patients who did not suffer NAFLD, NAFLD patients had a 
~2.5-fold higher risk of polyps and a ~2-fold higher risk of adenomatous polyps. Huang et 
al. [43] compared patients who developed adenoma after an initial negative baseline 
colonoscopy (adenoma group) with those who had a second negative colonoscopy (non-
adenoma group) and found NAFLD to be an independent risk factor for colorectal 
adenoma development following a negative baseline colonoscopy. The risk was higher in 
patients who suffered from NAFLD and other comorbidities, such as hypertension, 
smoking or MetS. In a study by Touzin et al. [44], the researchers compared patients who 
had previous biopsy had confirmed simple steatosis or NASH with the control group for 
whom sonographic imaging had not indicated fatty liver disease. They found a potential 
increased polyp burden for patients with fatty liver disease compared with the control. 
 
5. Association between non-alcoholic fatty liver disease and colorectal cancer 
Cigarette smoking, obesity and a high alcohol intake are indicated as factors causing 
increased risk of CRC in several guidelines for colorectal cancer screening. Accordingly, 
individuals who partake in such behavior are encouraged to undergo colonoscopy at 
younger age [45]. Obesity and MetS are associated with an increased cancer risk, and 
new evidence suggests an association between NAFLD and CRC. As a result, patients 
with NAFLD should also consider colonoscopy at an earlier age [37, 46]. In their 2012 
study, Lee et al. [39] analyzed Korean 5517 women and discovered a significant 
association between NAFLD and with an increased incidence of colorectal cancer among 
their subjects. All manifestations of the syndrome might be predictors of the development 
of colorectal neoplasms [39]. Wong et al. [40] found compared to healthy controls, NAFLD 
patients, diagnosed through magnetic resonance spectroscopy and liver biopsy, had 
significantly higher risk of colorectal adenomas and advanced colorectal neoplasm. 
Interestingly, patients with NAFLD and NASH usually develop colorectal adenomas and 
advanced neoplasms in the right sided colon. The association between NASH and 
colorectal neoplasm was observed independent of demographic and metabolic variables 
[40]. In a study conducted in Austria [41], CRC precursor lesions and early CRC were 
significantly more commonly seen in patients with NAFLD undergoing colonoscopy, in 
comparison with the control group. The increased risk was independent of other 
symptoms of IR. The investigators showed that in males, NAFLD increased the likelihood 
of CRC and lesions of rectum. In females, NAFLD increased the prevalence of lesions in 
proximal colon [41]. Lin et al. in a cohort study [45], found using colorectal biopsy and 
NAFLD, diagnosed though ultrasound imaging, a higher prevalence of CRMN in NAFLD 
patients. Similarly, sigmoid carcinoma and highly differentiated colorectal 
adenocarcinoma were more commonly found in subjects with NAFLD. According to these 
findings, physicians should urge patients with NAFLD to undergo colorectal screening 
[45]. By examining routine abdominopelvic computed tomography (CT) images taken for 
staging, Aktas et al. [47] investigated the relationship between NAFLD and CRC. Their 
retrospective study, involving 105 patients, found lower density on contrast 
abdominopelvic CT of colorectal cancer patients which agrees with a NAFLD diagnosis 
[47]. Basyigit et al. [28] evaluated the risk for CRC in patients with NAFLD in relation to 
IR. NAFLD was diagnosed by US. IR was assessed by the homeostatic model of 
assessment of IR. Employing multivariate logistic regression analysis, the researchers 
discovered a significant association between the presence of IR and the risk for colorectal 
adenoma and carcinoma. Moreover, the risk for CRC was significantly associated with 
the absence of NAFLD. A significant association between CRC risk and absence of 
NAFLD was also observed. Concurrent absence of NAFLD and presence of IR was also 
significantly associated with high risk of CRC. The authors showed that the absence of 
NAFLD in the presence of IR can predict CRC [28]. A study conducted by Kim et al. [48] 
showed that NAFLD was associated with higher incidence rates of cancer. Unadjusted, 
age-sex-adjusted, and multivariable adjusted analysis consistently showed that NAFLD 
was significantly associated with HCC, CRC in males, and breast cancer in females. The 
researchers used ultrasonographic imaging to diagnose hepatic steatosis in the absence 
of other known liver disease, including alcoholic or viral hepatitis [48]. Ahn et al. [16] 
investigated the risk of colorectal neoplasia in relation to the presence and severity of 
NAFLD. NAFLD was detected using US. The study revealed a close association between 
the presence and severity of NAFLD and colorectal neoplasia and advanced colorectal 
neoplasia which bring to attention the need for physicians to be aware of the increased 
risk of colorectal neoplasia in patients with NAFLD.[16] In a study with 1793 subjects 
divided into four groups based on the status of NAFLD and MetS, Pan et al. [5] utilized 
relative excess risks of interaction (RERI), attributable proportion (AP), and synergy index 
(SI) to measure additive interaction. The authors found that NAFLD and MetS were risk 
factors for colorectal neoplasm and CRC, respectively. MetS was associated with an 
increased risk of CRC in patients with NAFLD as well. It was thus suggested that patients 
with NAFLD and MetS undergo colonoscopic examination at regular intervals [5]. In 
another study, Yang et al. [49] recruited patients with both index and surveillance 
colonoscopy. This study demonstrated that in surveillance colonoscopies in patients with 
any adenoma at the index colonoscopy, NAFLD had little influence on the occurrence of 
CRN. This finding leads to the possibility that NAFLD is more closely linked to the initiation 
of CRN. Consequently, NAFLD can be seen an important risk factor in patients with 
negative index colonoscopy who demand surveillance colonoscopy [49]. In a meta-
analysis of observational studies by Mantovani et al. [3], the investigators aimed to 
measure the extent of the association between NAFLD and risk of both colorectal 
adenomas and cancer in asymptomatic individuals undergoing screening colonoscopy. 
The findings indicate that NAFLD is associated with a moderately elevated prevalence 
and occurrence of colorectal adenomas and cancer. It should be kept in mind that the 
observational design of the studies used does not permit the inference of causality, thus 
further investigation into the matter is required to shed light on the role hepatic 
contributors to increased risk of colorectal tumors for patients with NAFLD [3]. Ze et al. 
[50] evaluated the relationship between the fatty liver index, which predicts NAFLD, and 
the prevalence of colorectal adenomas. 2976 subjects over 40 years old who underwent 
routine checkups, including abdominal US and colonoscopy, were examined. The 
researchers found high fatty liver index could be a helpful predictor of colorectal adenoma 
[50]. Table 1 summarizes the studies that have investigated CRC in NAFLD patients. 
Regarding the evidence about the relationship between CRC and NAFLD, screening of 
patients with high risk of liver fibrosis, as suggested by Dyson et al. and Chalasani et al. 
seems a reasonable approach [63, 64]. Although there is insufficient evidence about CRC 
screening, we would suggest screening in at high-risk patients with NAFLD (Figure 2). 
Further studies are required regarding the cost effectiveness of such screening.  
 
6. Pathological mechanisms linking non-alcoholic fatty liver disease and colorectal 
cancer 
Although the exact mechanism behind the association between NAFLD and 
developing colorectal neoplasm is not clear, a recent meta-analysis has suggested 
possible relationship between these two clinical conditions [51]. It has been proposed that 
the NAFLD alone cannot be the exact reason behind developing colorectal neoplasms 
and presence of other risk factors will be mandatory. Some researchers such as Yang et 
al. has proved the relation between NAFLD and colorectal neoplasm and also suggest 
that NAFLD should be considered as an important factor for determining the screening 
colonoscopy intervals [52]. There are some explanation about the link between NAFLD 
and developing cancer which can be categorized in to four main groups. The most studied 
explanation is related to IR. The most likely mechanism associated with IR is due to 
Insulin-like growth factor-1 axis and hyperinsulinemic state which results in anti-apoptotic 
and proliferative effects [53]. The other explanation is related to adipose tissue 
dysfunction. As same as IR, the anti-apoptotic and proliferation effects are also seen with 
up-regulation of many pathways such as leptin/ AMP-activated protein kinase (AMPK) 
and resistin/NF-kB or down regulation of adiponectin/caspase or tumor necrosis factor-α 
(TNF-α) activation [53]. It has been shown that NAFLD patients have decreased levels of 
adiponectin and increased level of leptin secreted by adipose tissue. In addition to the 
potentially carcinogenic effects of leptin, adiponectin will appears to have anti-
cancerogenic effects by inducing caspase dependent endothelial cell apoptosis. Also, 
decrease in adiponectine level, the inhibitory effect on TNF-α is no longer available and 
tumor angiogenesis and proliferation will develop [53, 54]. Inflammation and alteration in 
gut microbiota are the two other explanation which results in inflammation [53, 55]. 
NAFLD and CRC patients mostly develop dysbiosis. Alteration gut microbiota will result 
in disruption bacterial metabolites and therefore inducement of activation of toll-like 
receptors (TLRs) which will further result in tumorigenesis [55]. By combining this 
evidence and by considering that NAFLD and visceral adipose tissue as the main 
component of central obesity axis, the explanation of the NAFLD effect of gastrointestinal 
neoplasms will become more evident. NAFLD itself and its dysbiosis as a low 
inflammatory state can build up an environment suitable for developing colorectal 
neoplasms as well as intrahepatic ones. This chronic inflammation alongside IR 
hyperinsulinemia will result in development of proliferation and anti-apoptotic effects 
necessary for developing different neoplasms. Disruption of adipokines, especially 
adiponectin, will further result in failure of anti-neoplastic effects and increase in pro-
neoplastic effects of other adipokines such as leptin. Also recently, the role of different 
microRNAs (miRNA or miR) has been proposed in development of NAFLD. miRNAs are 
short single stranded molecules composed about of ~22 nucleotides which can play 
different role cellular pathways and gene expression and especially in carcinogenesis 
[56]. miR-21 which is oncogene and miR-451 which act as tumor suppressor are 2 good 
example of important micoRNAs which are seen during NAFLD development [57, 58]. 
These two microRNAs are also reported to important in CRC pathogenesis. The possible 
effect of these shared microRNAs in NAFLD and CRC needs further studies to establish 
a cause effect relation. 
 
7. Expert commentary: Various molecular/cellular mechanisms, including inflammatory, 
apoptotic and proliferation pathways, are altered during the development of NAFLD, 
which are also important in CRC tumorigenesis, suggesting that prevention of NAFLD 
development may be a rational approach in the prevention of CRC. Despite of recent 
advances in molecular techniques for identifying the nature of various diseases, however 
still we are facing many gaps in our knowledge toward the understanding of the link 
between different diseases. Metabolic syndrome and obesity as well as NAFLD are 
considered as important role players in developing CRC and the link between these 
clinical conditions is now gathering as pieces of a puzzle in different researches. The most 
challenging issue for the researchers is gathering these pieces of puzzles in order to draw 
a conclusion regarding the exact effects of such clinical conditions. Beside this challenge, 
another which seems to be neglected is the effect of anti-cancer regimens for CRC 
patients who have NAFLD. Many of these drugs are metabolized in liver and in those who 
have liver dysfunction may face abnormal drug levels and inappropriate drug response.  
Chronic liver diseases such as NAFLD are now being considered as a possible risk factor 
for colorectal cancer. There is growing body of evidence showing the potential role of 
activation of pro-inflammatory, disruption of anti-inflammatory pathways, increasing the 
activity of pathways involved in cell proliferation/survival, such as Akt/PI3K, Wnt, TGF-b 
pathways. Thus targeting these dysregulated pathways via novel inhibitors can be a 
potential therapy for CRC prevention in cases with NAFLD. Moreover parallel targeting of 
other pathway (e.g., NF-κB, TNF and JNK) are needed to prevent the possible feedback 
loop between these pathways. Combination therapy and parallel targeting of key 
dysregulated pathways (e.g., NF-κB, TNF, Wnt/PI3K pathways) in NAFLD cases for CRC 
prevention should be considered. 
 
8. Five-year view 
 In the next five years the incidence of CRC and NAFLD will be increased and more 
research interest will be aimed at these two topics. It seems that the 5-year survival rate of the 
CRC will be increased according to recent advances in possible therapeutic approaches. 
According to recent studies, there is rapid growing evidence about the possible molecular 
mechanisms linking chronic disease such as NAFLD to different cancers such as CRC.  
Among various molecular mechanisms altered during development of NAFLD, some 
important in tumorigenesis. Alteration in inflammatory pathways and proliferation 
disruption as well as reduced apoptosis are considered as main effects during colorectal 
carcinogenesis. Further researches would be aimed on evaluating the effect of targeting 
theses pathways in controlling CRC. Prevention of NAFLD development by targeting 
these common pathways will be the reasonable approach in developing prevention 
strategies for CRC and further experimental research is warranted. Furthermore, the 
effect of some medications which are effective on treating NASH or can improve liver 
function on development of CRC is not clearly studied. It seems that studying the effect 
of such drugs, especially metformin on development of CRC in NAFLD patients can 
answer more questions about the widespread use of such drug in NAFLD patients.  
 
9. Key points: 
 - Chronic liver diseases such as NAFLD are becoming a major concern and are 
now being considered as a possible risk factor for different cancers, especially CRC. 
- Various molecular mechanisms are altered during the development of NAFLD, 
which are important in tumorigenesis in different sites of the body. 
- Alteration in inflammatory pathways and proliferation disruption as well as 
reduced apoptosis are considered as main effects during colorectal la carcinogenesis.  
- According to recent findings, prevention of NAFLD development may be a 
reasonable approach in the prevention of CRC.  
- Targeting the effective molecules in pathways involved in NAFLD pathogenesis 
is a potential therapy for CRC prevention.   
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 Table1. Summary of the most relevant studies investigating role of non-alcoholic fatty liver disease in colorectal cancer 
Author and 
year 
Country 
of 
populatio
n under 
study 
Population 
NAFLD 
detection 
method 
Main findings Ref 
Lee et al., 
2011  Korea 5517 female participants US Significant correlation between NAFLD  and development of CRC [39] 
Wong et al., 
2011  China 
199 NAFLD and  111  
without NAFLD 
PMRS or 
biopsy 
Higher risk developing colorectal adenomas and advanced neoplasm in NAFLD 
patients [40] 
Stadlmayr et 
al., 2011 Austria 
1211 participants (632 
NAFLD) US 
Significantly more CRC precursor lesions and were more likely to develop CRC in 
NAFLD patients [41] 
Lin et al., 
2014  China 
2315 participants (2052 
NAFLD) US NAFLD was an independent risk factor for CRC [45] 
Aktas et al., 
2014  Turkey 105 CRC CT Significantly higher prevalence of NAFLD in CRC patients [47] 
Basyigit et 
al., 2015  Turkey 127 NAFLD US Significantly correlation between absence of NAFLD and risk for CRC [28] 
Kim et al., 
2017  Korea 25947 participants US Strong association between NAFLD and development of CRC In male [48] 
Ahn et al., 
2017  Korea 26540 participants US 
Strong association between presence and severity of NAFLD and advanced 
colorectal neoplasia [16] 
Pan et al., 
2017  China 1793 participants US 
NAFLD is among the risk factors for neoplasm and CRC. It also has an additive effect 
on the development of CRC [5] 
Yang et al., 
2017 Korea 1023 participants US or CT Correlation between occurrence of colorectal neoplasia and NAFLD [49] 
Mantovani et 
al., 2018  
Meta-
analysis 
11 studies including 
91124 participants 
imaging or 
biopsy 
NAFLD is independently correlated with a moderately elevation in incidence of 
colorectal adenomas and CRC [3] 
Ze et al., 
2018  Korea 2976 patients US High fatty liver index can be used to predict colorectal adenoma [50] 
NAFLD: non-alcoholic fatty liver disease; CRC: colorectal cancer; US: ultrasonography; PMRS: proton magnetic resonance spectroscopy; CT: 
computed tomography; IR: insulin resistance 
 
Figure 1. This schematic figure illustrates the possible relation between NAFLD and 
developing CRC. Accumulation of fat in liver results in gradual changes and 
development of NAFLD. There are many different factors suggested for these chronic 
changes. miR-21 and miR-451 are one of important mechanism which could be 
effective in pathogenesis of both NAFLD and CRC. During NAFLD alteration in different 
cellular pathways occur. Overproduction of many chemicals and inflammatory factors 
such as CRP and interleukins along with reduced production of other factors such as 
adiponectin provide a favorable environment for tumor growth including CRC 
 
 
Figure 2. Patients under 65 years who were referred with abnormal liver function tests 
and ultrasound of liver may need screening for CRC in their possible NAFLD settings.  
* The significant amount of alcohol consumption in NAFLD patients has not largely 
evaluated. 
** Some well-known causes of macrovascular steatosis include: Wilson disease, 
lipodystrophy, abetalipoproteinemia and certain medications including tamoxifen, 
corticosteroids and etc.  
*** Some well-known causes of microvascular include: inborn errors of metabolism, 
Reye’s syndrome and certain medications including valproate and etc. 
ARFI, acoustic radiation force impulse; ELF, enhanced liver fibrosis; FIB-4, fibrosis-4; 
HCC, hepatocellular carcinoma; NAFLD, 
non-alcoholic fatty liver disease; CRC, colorectal cancer.
 
